Osteogenesis Imperfecta (OI)-Pipeline Insight, 2020

Osteogenesis Imperfecta (OI)-Pipeline Insight, 2020

  • DelveInsight
  • February 2020
  • Pharmaceutical
  • 106 pages
1. Report Introduction
2. Osteogenesis Imperfecta (OI)
2.1. Overview
2.2. History
2.3. Osteogenesis Imperfecta (OI) Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Osteogenesis Imperfecta (OI) Diagnosis
2.6.1. Diagnostic Guidelines
3. Osteogenesis Imperfecta (OI) Current Treatment Patterns
3.1. Osteogenesis Imperfecta (OI) Treatment Guidelines
4. Osteogenesis Imperfecta (OI) - DelveInsight's Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Osteogenesis Imperfecta (OI) companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Osteogenesis Imperfecta (OI) Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Osteogenesis Imperfecta (OI) Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Osteogenesis Imperfecta (OI) Late Stage Products (Phase-III)
7. Osteogenesis Imperfecta (OI) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Osteogenesis Imperfecta (OI) Discontinued Products
13. Osteogenesis Imperfecta (OI) Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report?
14. Osteogenesis Imperfecta (OI) Key Companies
15. Osteogenesis Imperfecta (OI) Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Osteogenesis Imperfecta (OI) Unmet Needs
18. Osteogenesis Imperfecta (OI) Future Perspectives
19. Osteogenesis Imperfecta (OI) Analyst Review
20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
Table 1: Osteogenesis Imperfecta (OI) Diagnostic Guidelines
Table 2: Osteogenesis Imperfecta (OI) Treatment Guidelines
Table 3: Assessment Summary
Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5: Osteogenesis Imperfecta (OI) Acquisition Analysis
Table 6: Assessment by Phase of Development
Table 7: Assessment by Product Type (Mono / Combination)
Table 8: Assessment by Stage and Product Type
Table 9: Assessment by Route of Administration
Table 10: Assessment by Stage and Route of Administration
Table 11: Assessment by Molecule Type
Table 12: Assessment by Stage and Molecule Type
Table 13: Assessment by MOA
Table 14: Assessment by Stage and MOA
Table 15: Assessment by Target
Table 16: Assessment by Stage and Target
Table 17: Osteogenesis Imperfecta (OI) Late Stage Products (Phase-III)
Table 18: Osteogenesis Imperfecta (OI) Mid Stage Products (Phase-II)
Table 19: Osteogenesis Imperfecta (OI) Early Stage Products (Phase-I)
Table 20: Pre-clinical and Discovery Stage Products
Table 21: Inactive Products
Table 22: Dormant Products
Table 23: Discontinued Products
Figure 1: Disease Overview
Figure 2: History
Figure 3: Symptoms
Figure 4: Causes
Figure 5: Pathophysiology
Figure 6: Diagnostic Guidelines
Figure 7: Treatment Guidelines
Figure 8: Osteogenesis Imperfecta (OI) companies collaborations, Licensing, Acquisition -Deal Value Trends
Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10: Osteogenesis Imperfecta (OI) Acquisition Analysis
Figure 11: Assessment by Phase of Development
Figure 12: Assessment by Product Type (Mono / Combination)
Figure 13: Assessment by Stage and Product Type
Figure 14: Assessment by Route of Administration
Figure 15: Assessment by Stage and Route of Administration
Figure 16: Assessment by Molecule Type
Figure 17: Assessment by Stage and Molecule Type
Figure 18: Assessment by MOA
Figure 19: Assessment by Stage and MOA
Figure 20: Late Stage Products (Phase-III)
Figure 21: Mid Stage Products (Phase-II)
Figure 22: Early Stage Products (Phase-I)
Figure 23: Pre-clinical and Discovery Stage Products
Figure 24: Inactive Products
Figure 25: Dormant Products
Figure 26: Discontinued Products
Figure 27: Unmet Needs

Have query on this report?

Success Stories

Our Clients

Tell Us What You Need and We’ll Get Back with the Best Solutions Available.

*
*
*

get in touch

Location :

State Tower, 90 State Street, Suite 700, Albany NY - 12207, United States

Call Us :

US/Canada toll free : 866-997-4948

Tel : +1-518-621-2074